| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | WVS; ENX1; KMT6; WVS2; ENX-1; EZH2b; KMT6A |
| WB Predicted band size | 85 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human EZH2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于EZH2抗体的3篇代表性文献，涵盖其在不同研究中的应用和意义：
---
1. **文献名称**：*EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells*
**作者**：Kleer CG et al.
**摘要**：该研究通过免疫组化(IHC)分析EZH2蛋白在乳腺癌中的表达，发现EZH2高表达与肿瘤侵袭性和不良预后显著相关。研究利用特异性EZH2抗体验证其在乳腺癌细胞增殖和表观遗传调控中的作用，提出EZH2可作为乳腺癌的生物标志物。
---
2. **文献名称**：*Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin*
**作者**：Morin RD et al.
**摘要**：通过Western blot和免疫沉淀技术，研究揭示了EZH2基因在淋巴瘤中的高频突变(如Y641位点)，并开发了针对突变型EZH2的特异性抗体。该突变导致组蛋白H3K27异常甲基化，促进淋巴瘤发生，为靶向治疗提供依据。
---
3. **文献名称**：*Targeted disruption of the EZH2–EED complex inhibits oncogenic transformation by polycomb repressive complex 2*
**作者**：Kim KH et al.
**摘要**：研究通过ChIP-seq和免疫荧光技术，使用EZH2抗体验证其与EED的相互作用对PRC2复合体功能的重要性。发现破坏EZH2-EED结合可抑制癌细胞增殖，为开发小分子抑制剂(如DZNep)阻断EZH2活性提供理论基础。
---
**备注**：以上文献均聚焦EZH2抗体的应用，包括癌症标志物检测、突变分析和机制研究。如需具体期刊信息和年份，可进一步补充数据库检索(如PubMed ID)。
EZH2 (Enhancer of Zeste Homolog 2) is a catalytic subunit of the Polycomb Repressive Complex 2 (PRC2), which mediates epigenetic gene silencing through methylation of histone H3 on lysine 27 (H3K27me3). This post-translational modification represses transcription of target genes, playing critical roles in cell differentiation, proliferation, and stem cell maintenance. Dysregulated EZH2 expression or activity is implicated in various cancers, including lymphomas, breast, prostate, and ovarian cancers. Overexpression of EZH2 is often associated with aggressive tumor behavior and poor prognosis, as it silences tumor suppressor genes. Conversely, specific gain-of-function mutations in EZH2 drive aberrant H3K27 methylation in certain hematologic malignancies.
EZH2 antibodies are essential tools for studying its expression, localization, and functional interactions in both normal and disease contexts. They are widely used in techniques like immunohistochemistry (IHC), Western blotting, chromatin immunoprecipitation (ChIP), and immunofluorescence to assess EZH2 levels in tissues or cell lines. In clinical research, EZH2 antibodies help validate its role as a biomarker for cancer progression or therapeutic targeting. Recent drug development has focused on EZH2 inhibitors (e.g., tazemetostat) to counteract its oncogenic activity, particularly in cancers with PRC2 pathway alterations. However, EZH2's context-dependent roles—acting as either an oncogene or tumor suppressor—highlight the need for precise diagnostic tools, underscoring the importance of validated, high-specificity antibodies in both research and clinical applications.
×
